NHS England updates CDF List

NHS England has updated the Cancer Drugs Fund List. The latest version (v1.313) was uploaded to the NHS England Website on Friday 28, June 2024.

The following changes have been introduced:

Daratumumab in combination with bortezomib, cyclophosphamide and dexamethasone (DAR5)

For the treatment of newly diagnosed and treatment-naive patients with systemic immunoglobulin light chain amyloidosis (AL) where the following criteria have been met:

Moved into routine commissioning - section B of list

Olaparib in its tablet formation (OLAP1a)

For the maintenance treatment in patients with high grade epithelial stage III or ovarian, fallopian tube or primary peritoneal carcinoma who are in response following platinum-based FIRST line chemotherapy AND who have a deleterious or suspected deleterious germline and/or somatic BRCA mutation where the following criteria have been met: THIS FORM IS FOR INITIATION OF MAINTENANCE OLAPARIB AS A SINGLE AGENT ONLY. THIS FORM IS FOR INITIATION OF MAINTENANCE OLAPARIB TABLETS IN THIS INDICATION. A separate CDF form OLAP1b is only for those patients with stable residual disease for whom it is appropriate to continue maintenance olaparib tablets after completion of years of maintenance olaparib therapy. OLAP1b must be completed in such patients for funding of olaparib tablets continue beyond 2 years A separate form (OLAP4) is to be used olaparib in combination with bevacizumab as maintenance treatment in this 1st line indication.

Moved into routine commissioning - section B of list

NA (ELR1)

Treatment criteria (#17) updated